High Lp(a) Polygenic Risk Score

Roughly one in five adults walks around with a hidden, inherited driver of heart attacks called Lp(a), short for lipoprotein(a). It rarely shows up on a standard cholesterol panel, and your level is decided almost entirely by the DNA you were born with. This test reads dozens of those inherited DNA differences at once to estimate how strongly your genetics push your Lp(a) up.

If your score is high, it means your DNA is set up to produce more of this particle for life, which translates into higher odds of coronary artery disease and earlier heart attacks. Knowing this number once gives you a head start on the kind of aggressive prevention that someone with average inherited risk does not need to think about.

One important caveat up front: the 2026 ACC/AHA dyslipidemia guidelines state that for clinical purposes, a direct Lp(a) blood measurement is sufficient and genetic testing for Lp(a) is not advised as the primary tool for cardiovascular risk assessment. The polygenic score is best understood as a research-grade and exploratory tool that can add context, particularly when direct Lp(a) measurement is unavailable or when explaining inherited patterns of high cholesterol in a family.

What This Score Is Actually Reading

Lp(a) (lipoprotein(a)) levels are about 70 to 90 percent determined by genetics, and almost all of that signal sits in or near a single gene called LPA. A polygenic risk score (a weighted sum of many small DNA differences) at this gene can capture as much as 60 percent of the differences in measured Lp(a) levels seen between people of European ancestry. In other words, the score is mostly acting as a genetic proxy for the Lp(a) level you have been carrying your entire life.

One commonly used version of this score combines 43 separate DNA changes at the LPA gene. It has been tested in two of the largest genetic biobanks in the world, the UK Biobank and the Million Veteran Program, and is most accurate in people of European ancestry. It performs less well in people of African, South Asian, and East Asian ancestry, where the genetic architecture of Lp(a) differs.

Heart Attack and Coronary Artery Disease Risk

In a UK Biobank analysis, people with a higher inherited Lp(a) score had a meaningfully higher risk of developing atherosclerotic cardiovascular disease (a buildup of plaque that causes heart attacks and strokes). The risk rose by about 29 percent per roughly 120 nmol/L increase in the score, very similar to the risk increase seen with directly measured Lp(a). The two essentially measured the same underlying biology.

In a study of nearly 23,000 veterans who had undergone coronary angiograms (a direct look inside the arteries of the heart), a high Lp(a) genetic score was tied to more severe blockages. The link was strongest for the kind of obstructive plaque that actually blocks blood flow, and it held even after accounting for LDL cholesterol and other standard risk factors.

A separate analysis of more than 76,000 people combined a polygenic Lp(a) score with a related genetic marker (a repeating DNA segment called KIV-2 that also influences Lp(a)). People in the high-genetic-risk group had about 60 percent higher risk of coronary artery disease than those in the low-risk group, with earlier onset of heart attacks, heart failure, and other forms of atherosclerotic disease. Many of those affected had no traditional risk factors at all, the kind of patient who looks fine on a standard checkup and then has a heart attack at 50.

Familial Hypercholesterolemia and Unexplained High Cholesterol

Familial hypercholesterolemia (FH) is an inherited condition that causes very high LDL cholesterol from birth. In the 100,000 Genomes Project, an Lp(a) polygenic score was significantly higher in people clinically diagnosed with FH than in controls. About 18.5 percent of patients with the FH phenotype, but no detectable FH-causing gene mutation, carried a high Lp(a) genetic score instead. This matters because Lp(a) contains its own cholesterol, which can inflate an LDL reading and mimic FH on a lipid panel.

If your cholesterol has always been higher than your lifestyle would predict, or if FH runs in your family but no single causal mutation has been found, an Lp(a) polygenic score can help explain what is going on. It can change how aggressively your cholesterol is treated and whether your relatives should also be screened.

What This Score Adds Beyond Standard Risk Calculators

When the Lp(a) genetic score is added to a widely used clinical heart-disease calculator (QRISK3), the improvement in predictive accuracy is real but modest. The technical measure of discrimination rose from 0.640 to 0.642, a small bump similar to what direct Lp(a) measurement adds. The reason the score does not add more on top of measured Lp(a) is straightforward: it is mostly a genetic estimate of the same number. Once you actually know your Lp(a) level, the genetic score adds little extra information. This is why current ACC/AHA guidance favors direct Lp(a) measurement for clinical decision-making.

The genetic score is most informative when direct Lp(a) is not available, when you want a one-time read that captures your lifelong inherited risk, or when you want to understand why your Lp(a) is elevated or why heart disease keeps appearing in your family.

When Results Can Be Misleading

• Ancestry limits accuracy: most published Lp(a) polygenic scores were built in people of European ancestry. They explain a much smaller share of Lp(a) variation in people of African, South Asian, and East Asian ancestry, so a low score in a non-European individual does not rule out high Lp(a) as confidently as the same result would in a European.
• Variant coverage: the score reads only the DNA differences it was designed to detect. Rare large LPA variants, including unusual repeat lengths (the KIV-2 region), can independently raise Lp(a) and may not be fully captured by the standard score.
• Score is a proxy, not a measurement: the score predicts Lp(a) tendency, not your actual level. Two people with the same score can still have somewhat different measured Lp(a). A direct Lp(a) blood test is the gold standard for confirming where you actually stand and is the test endorsed by current clinical guidelines.
• Variants of uncertain significance: some DNA changes in or near LPA do not have a clearly established effect on Lp(a) levels, which can affect how a score is calculated and interpreted at the margins.
• Clinical-grade vs direct-to-consumer testing: results from a clinical laboratory and a consumer ancestry kit may use different variant panels and weighting, leading to different scores even for the same person.
• Not a measure of LDL or other lipids: a high Lp(a) genetic score tells you nothing about your LDL cholesterol, ApoB, or triglyceride pathways. Those need to be measured separately.

One-Time Result, Lifetime Action

Your DNA does not change, so this score is a one-time test. There is no benefit to repeating it. The value comes from acting on it for years. After getting this result, the useful tracking happens with companion tests: direct Lp(a) measurement to confirm your actual level, and regular lipid panels including ApoB and LDL cholesterol to make sure the rest of your cardiovascular picture is well controlled. For someone with a high Lp(a) genetic score, aim for at least annual lipid testing, with more frequent checks (every 3 to 6 months) when you are starting or adjusting a cholesterol-lowering medication.

What to Do With a High Score

A high Lp(a) polygenic risk score is a signal to act, not panic. The first step is to confirm with a direct Lp(a) blood test, which is the measurement clinical guidelines rely on for decision-making. If your measured Lp(a) is also high, your cardiovascular risk should be managed more aggressively. That generally means lowering LDL cholesterol and ApoB further than would be recommended for someone with average Lp(a), often with statin therapy or, in select cases, PCSK9 inhibitors (a newer class of cholesterol-lowering injections that can also reduce Lp(a) by roughly 15 to 30 percent).

A high score should also prompt a family conversation. First-degree relatives (parents, siblings, children) share enough of your DNA that they may carry the same inherited risk. The 2026 ACC/AHA guidelines recommend cascade screening of first-degree relatives using a direct Lp(a) blood measurement rather than genetic testing. If you have a strong family history of premature heart attacks, especially before age 55 in men or 65 in women, talk with a preventive cardiologist or lipidologist (a specialist in inherited cholesterol disorders) about how aggressively to intervene. Many specialists also recommend coronary calcium scoring and detailed lipid testing such as ApoB and NMR particle counts as part of the workup, though these are expert-opinion additions rather than guideline-mandated for every patient with high Lp(a) genetic risk.